These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15160302)

  • 21. Anthrax attack in the USA.
    McCarthy M
    Lancet Infect Dis; 2001 Dec; 1(5):288-9. PubMed ID: 11871791
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
    Gill SC; Rubino CM; Bassett J; Miller L; Ambrose PG; Bhavnani SM; Beaudry A; Li J; Stone KC; Critchley I; Janjic N; Heine HS
    Antimicrob Agents Chemother; 2010 May; 54(5):1678-83. PubMed ID: 20145081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCR-based detection of Bacillus anthracis in formalin-fixed tissue from a patient receiving ciprofloxacin.
    Levine SM; Perez-Perez G; Olivares A; Yee H; Hanna BA; Blaser MJ
    J Clin Microbiol; 2002 Nov; 40(11):4360-2. PubMed ID: 12409432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L; de Andrade C; Dalla Costa T
    Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility to antibiotics of Bacillus anthracis strains isolated in Romania.
    Caplan DM; Ivana S; Caplan ME
    Roum Arch Microbiol Immunol; 2009; 68(2):106-10. PubMed ID: 20361530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioterrorism. Researchers question obsession with Cipro.
    Enserink M
    Science; 2001 Oct; 294(5543):759-61. PubMed ID: 11679638
    [No Abstract]   [Full Text] [Related]  

  • 28. Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
    Grohs P; Podglajen I; Gutmann L
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3024-7. PubMed ID: 15273116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
    Louie A; Vanscoy BD; Heine HS; Liu W; Abshire T; Holman K; Kulawy R; Brown DL; Drusano GL
    Antimicrob Agents Chemother; 2012 Jan; 56(1):513-7. PubMed ID: 22064542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
    Firsov AA; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
    Booker BM; Smith PF; Forrest A; Bullock J; Kelchlin P; Bhavnani SM; Jones RN; Ambrose PG
    Antimicrob Agents Chemother; 2005 May; 49(5):1775-81. PubMed ID: 15855495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newly developed colorimetric drug screening assay for Bacillus anthracis.
    Barrow EW; Valderas MW; Bourne PC; Barrow WW
    Int J Antimicrob Agents; 2006 Feb; 27(2):178-80. PubMed ID: 16423510
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
    Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
    J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacillus anthracis and antibacterial agents.
    Bryskier A
    Clin Microbiol Infect; 2002 Aug; 8(8):467-78. PubMed ID: 12197869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
    Heine HS; Bassett J; Miller L; Bassett A; Ivins BE; Lehoux D; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3350-7. PubMed ID: 18606841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
    Heine HS; Purcell BK; Bassett J; Miller L; Goldstein BP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):991-6. PubMed ID: 20047912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
    Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
    J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.